What is the correct order when drawing rapid-acting through to long-acting insulins?

What is the correct order when drawing rapid-acting through to long-acting insulins?

• A. Lispro/aspart, Regular, NPH, Glargine
• B. Glargine, NPH, Regular, Lispro
• C. NPH, Regular, Lispro, Glargine
• D. Lispro, Glargine, Regular, NPH

Answer: (A)

The main idea is to draw insulin from fastest-acting to slowest-acting when multiple types are prepared for administration. Rapid-acting insulins (lispro or aspart) act the quickest, so they’re drawn first, followed by short-acting Regular insulin, then intermediate-acting NPH, and finally long-acting glargine. This sequence aligns with their onset and duration—rapid-acting starting in about 15 minutes, Regular in about 30–60 minutes, NPH roughly 1–2 hours, and glargine providing a steady effect without a pronounced peak for about a full day. Drawing in this order helps preserve each insulin’s expected action and reduces cross-contamination risk. Note that long-acting insulin is often given with its own syringe and should not be mixed with others, but if the scenario involves drawing into one syringe, the order above is the correct progression.

The main idea is to draw insulin from fastest-acting to slowest-acting when multiple types are prepared for administration. Rapid-acting insulins (lispro or aspart) act the quickest, so they’re drawn first, followed by short-acting Regular insulin, then intermediate-acting NPH, and finally long-acting glargine. This sequence aligns with their onset and duration—rapid-acting starting in about 15 minutes, Regular in about 30–60 minutes, NPH roughly 1–2 hours, and glargine providing a steady effect without a pronounced peak for about a full day. Drawing in this order helps preserve each insulin’s expected action and reduces cross-contamination risk. Note that long-acting insulin is often given with its own syringe and should not be mixed with others, but if the scenario involves drawing into one syringe, the order above is the correct progression.